Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes.

Ji-Won KimYe-Jee LeeYoung-Hye YouMin Kyong MoonKun-Ho YoonYu-Bae AhnSeung Hyun Ko

Published in: Journal of cellular biochemistry (2018)

We suggest that this metabolic improvement might be related to SIRT1 and AMPK pathway in T2DM. But empagliflozin is thought to have more advantage to prevent hepatic steatosis than voglibose in T2DM.

Keyphrases

skeletal muscle
oxidative stress
molecular docking
glycemic control
ischemia reperfusion injury
metabolic syndrome
adipose tissue
protein kinase
weight loss